Posted in | Oncology

Landscape and Dynamics of the Tumor Immune Microenvironment of Liver Cancer and Colorectal Cancer Liver Metastasis

Liver cancer has the third most lethality in the world, and hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancer. 

HCC is highly prevalent in China, with more than 50% of patients infected by the hepatitis B virus (HBV). The liver is a common site for tumor metastasis, with about 50% of colorectal cancer (CRC) patients developing liver metastasis. 

Cancer immunotherapy has achieved remarkable results in clinical trials, while the therapeutic effects are uneven and the response rates in liver cancer and liver metastasized CRC are low. Thus, it is particularly important to explore different cell types in liver cancer and liver metastasized CRC, and decipher immune-regulation mechanisms in the TME of these cancer types. 

Utilizing two single-cell RNA sequencing (scRNA-seq) technologies, SMART-seq2 and 10x Genomics, Qiming Zhang and her colleagues generated transcriptome profiles for different tissues of multiple liver cancer and liver metastasized CRC patients. With a combination of bioinformatics analyses and experiments, they systematically delineated the expression characteristics, dynamic relationships in different tissues and potential biological functions of cell populations in the two cancer types. 

They also illustrated the interaction relationship of different cellular components in liver cancer. For different cancer types, they compared the TME of primary liver cancer, primary CRC, and CRC liver metastasis.

In this webinar, Qiming Zhang of MIT and Peking University will join Shuyun Ding from Vazyme to discuss this research. Watch a preview below. 

Are LAMP3- DC anti or pro-tumor-

Key learning objectives:

  • Learn to utilize two single-cell RNA sequencing to generate transcriptome profiles for different tissues of multiple liver cancer and liver metastasized CRC patients
  • Understand the interaction relationship of different cellular components in liver cancer
  • View the comparison between the TME of primary liver cancer, primary CRC, and CRC liver metastasis

About the event speakers

Qiming Zhang has an interdisciplinary background in bioinformatics and cancer immunology mainly using single-cell technologies and spatial transcriptomics. 

Qiming's research includes deciphering critical immune cell populations in the tumor microenvironment of liver cancer and liver metastasized colorectal cancer patients. Specifically, current immunotherapy regimens do not show significant efficacy in these patients, indicating the importance of understanding the regulation process of tumor-immune regulation and finding more effective therapeutic candidates. 

Based on valuable clinical samples and bioinformatics tools, Qiming has found a series of potential therapeutic targets, which led her to explore more fundamental mechanisms of these targets and the possibility of developing pre-clinical and clinical therapy strategies based on these targets.

Shuyun Ding is a technical support Engineer with Vazyme, assisting and resolving technical problems and operational issues in the Next-generation sequencing field. 

Who should attend this webinar:

This webinar is aimed at Biomedical Scientists, Clinical Scientists, Clinical Lab Managers/Directors, Senior Scientists/ Clinicians, POC/ MD, R&D Scientists, Company CEOs, CSOs, or anyone in the procurement department who is involved in buying decisions. Book your place below. 

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.